Next-generation sequencing (NGS), also known as massively parallel sequencing (MPS), offers broad detection of genetic alterations that, in approximately one-third of patients with cancer, are “actionable,” meaning that they can be targeted by available therapeutics or the detection of the alteration can lead to a change in therapy. NGS is useful in the diagnosis of patients, determining their prognosis, appropriate treatment selection, and clinical trial enrollment. Many testing panels are available, each with different abilities to detect various mutation types. Clinicians not only have to decide which test to use, but which specimen to test, and when and how often to test. Aside from unique mutations, immunotherapy markers have become important for the use of checkpoint inhibitors, and their detection and interpretation can also be challenging. Efforts are underway to simplify and validate these assays. Meanwhile, clinicians should become educated about the benefit of, means of, and interpretation of genomic testing patients across the disease course.
Disclosures: Dr. Morrissette has disclosed that she has received consulting fees from Novartis Pharmaceuticals Corporation and BioRad.
Correspondence: Jennifer J.D. Morrissette, PhD, University of Pennsylvania, 3020 Market Street, Suite 220, Philadelphia, PA 19104. Email: firstname.lastname@example.org
ZehirA, BenayedR, ShahRH, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients [published correction appears in Nat Med 2017;23:1004]. Nat Med2017;23:703–713.
ZehirA, BenayedR, ShahRH, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients [published correction appears in Nat Med 2017;23:1004]. Nat Med 2017;23:703–713.10.1038/nm.4333)| false
ZillOA, BanksKC, FaircloughSR, The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Can Res 2018;24:3528–3538.10.1158/1078-0432.CCR-17-3837)| false
ZhangY, ChangL, YangY, Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Mol Cancer 2019;18:7.3062640110.1186/s12943-019-0939-9)| false
AggarwalC, ThompsonJC, BlackTA, Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol 2019;5:173–180.3032599210.1001/jamaoncol.2018.4305)| false